The University of Barcelona (UB) and Hospital Clínic de Barcelona collaborate with Boehringer Ingelheim Inc. to improve the efficiency of nintedanib, an antiangiogenic and antifibrotic drug, for the treatment of lung cancer. This public-private collaboration enabled researchers identify molecular mechanisms underlying the lack of efficiency of this drug in squamous cell carcinoma, a sub-type of non-small cell lung cancer, and the important role of smoking in this lack of effectivity.
New advances in the treatment of adva... - Lung Conditions C...
New advances in the treatment of advanced lung cancer.
![2greys profile image](https://images.hu-production.be/avatars/a9ca17ff0998af8a344aa9e934606936_small@2x_100x100.jpg)
Written by
![2greys profile image](https://images.hu-production.be/avatars/a9ca17ff0998af8a344aa9e934606936_small@2x_100x100.jpg)
2greys
To view profiles and participate in discussions please or .
Read more about...
Not what you're looking for?
You may also like...
Cystic fibrosis
HiI was diagnosed with bronchiectasis at the beginning of the year, at the time it was mentioned i...
anyone having croaky throat problems with inhalers
i’m currently using Trimbow inhaler for COPD and unfortunately, I seem to be one in 10 people...
Blood thinners advice
Morning friends, on Thursday I had a third tachycardia episode - with the previous two my heart...
My first attempt at drawing with pencils for a few years ... Its the front elevation of Beaulieu palace 🙉
It's taken a while many rubbers many ripped up pages just something a little different from me...
Autumn covid booster (anti-vaxxers please scroll past)
I just spotted this...